検索結果

adquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that the orphan drug designation to the in-house developed compound having the development code SJP-0008 ...

Business Activities | About Senju | SENJU Pharmaceutical

Based on a sense of mission to contribute to the health of the eyes of people around the world, and a development policy that puts top priority on safety, we have always taken a pioneering path in oph...

tical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headquarters: Osak...

Compliance System | Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical

Code of Conduct for Compliance The directors, employees and other members of Senju Pharmaceutical Co., Ltd. (“SENJU”) will act in compliance not only with the law but will operate under a high standar...

Medical devices and healthcare | Business Activities | About Senju | SENJU Pharmaceutical

We will contribute to medical care and your health requirements in the new era through medical devices. Today, in the era of the 100-year-life, digital transformation is being promoted in various fiel...